Efficacy of birinapant in combination with carboplatin in targeting platinum‑resistant epithelial ovarian cancers.

ABSTRACT: Patients diagnosed with epithelial ovarian cancers (EOCs) often suffer from disease relapse associated with the emergence of resistance to standard platinum‑based chemotherapy. Treatment of patients with chemo‑resistant disease remains a clinical challenge. One mechanism of chemoresistance includes overexpression of pro‑survival proteins called inhibitors of apoptosis (IAP) which enable cancer cells to evade apoptosis. Due to their anti‑apoptotic activity, association with poor prognosis, and correlation with therapy resistance in multiple malignancies, IAP proteins have become an attractive target for development of anticancer therapeutics. Second mitochondrial activator of caspase (SMAC) mimetics are the most widely used IAP antagonists currently being tested in clinical trials as a mono

SUBMITTER: Singh T 

PROVIDER: S-EPMC8878637 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature